Top Clinical Trials companies in Germany by Price to Sales Ratio (P/S)

This ranking features the top 3 Clinical Trials companies in Germany ranked by Price to Sales Ratio (P/S), averaging a Price to Sales Ratio (P/S) of 11.91, for January 15, 2025.

Germany

Clinical Trials
Price to Sales Ratio (P/S)
#
Name
Price to Sales Ratio (P/S)
 Reported Date
Stock Price
Change
 Price (30 days) Country
1
5CV.F

CureVac N.V.

1

5CV.F

15.87

 Jan. 14, 2025 USD 3.95 -0.95%

Germany
2
MYNZ

Mainz Biomed B.V.

2

MYNZ

13.12

 Jan. 14, 2025 USD 5.29 13.28%

Germany
3
22UA.F

BioNTech SE

3

22UA.F

6.73

 Jan. 14, 2025 USD 116.36 -0.45%

Germany
Frequently Asked Questions
  • Which Clinical Trials company in Germany has the highest Price to Sales Ratio (P/S) ?

    The Clinical Trials company in Germany with the highest Price to Sales Ratio (P/S) is CureVac N.V. (Frankfurt Stock Exchange: 5CV.F) at 15.87.

  • Which Clinical Trials company in Germany has the lowest Price to Sales Ratio (P/S) ?

    The Clinical Trials company in Germany with the lowest Price to Sales Ratio (P/S) is BioNTech SE (Frankfurt Stock Exchange: 22UA.F) at 6.73.

  • What are the top 10 Clinical Trials companies in Germany by Price to Sales Ratio (P/S) ?

    The top 10 Clinical Trials companies in Germany by Price to Sales Ratio (P/S) are CureVac N.V., Mainz Biomed B.V. and BioNTech SE.

  • What are the bottom 10 Clinical Trials companies in Germany by Price to Sales Ratio (P/S) ?

    The bottom 10 Clinical Trials companies in Germany by Price to Sales Ratio (P/S) are BioNTech SE, Mainz Biomed B.V. and CureVac N.V..